In the management of NSTEMI, which option is incorrect when considering anticoagulation therapy?

Bivalirudin is primarily indicated for patients undergoing percutaneous coronary intervention (PCI) rather than for conservative management of non-ST elevation myocardial infarction (NSTEMI). In NSTEMI management, particularly in the conservative approach, heparin and fondaparinux are more commonly recommended due to their established roles in providing anticoagulation in the settings of NSTEMI and non-invasive treatment strategies. Clopidogrel is routinely utilized in NSTEMI management to provide antiplatelet effects for patients receiving conservative treatment or those waiting for PCI, enhancing outcomes when combined with anticoagulants. Fondaparinux is another favorable option that can be utilized, particularly in patients who may require anticoagulation but are not candidates for heparin. Therefore, suggesting that bivalirudin is preferred in conservative management is not consistent with current guidelines and practices, making that statement incorrect.